Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

Nexalin Technology (NXL) announced that three independently published, peer-reviewed clinical studies, coupled with a growing body of internal data, collectively demonstrate the ability of its proprietary 15 milliamp Gen-2 Nexalin DIFS technology-to improve cognition, restore brain activity, and enhance neuron connectivity in patients with Alzheimer’s disease. “The strength of these three publications lies in their convergence,” said Mark White, CEO of Nexalin Technology. “Each study explores a different dimension of the disease-cognition, regional activity, and functional connectivity-and all point to the same conclusion: Nexalin’s DIFS technology has the potential to restore brain networks and improve cognitive function in Alzheimer’s disease. Collectively, they represent one of the most compelling non-invasive data sets to date in this field.”